Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran20 enrolled

Overview

The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.

Symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion. Patients with this abnormality as an early manifestation of glucose intolerance are at higher risk of type 2 diabetes. The pathophysiology of this abnormality appears to be related with delayed first phase insulin release. Improvement of first phase insulin secretion and delay in gastric emptying induced by sitagliptin phosphate could have favorable effects in patients in whom delayed insulin secretion is associated with reactive hypoglycemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Reactive Hypoglycemia

Interventions

Sitagliptin phosphateDRUG

Sitagliptin phosphate 100 mg per day per 2 weeks

PlaceboDRUG

Placebo 1 tablet per day per 2 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical and biochemical diagnosis of prediabetic reactive hypoglycemia * Must be able to swallow tablet * Negative pregnancy test (when appropriate) Exclusion Criteria: * Renal insufficiency * Hepatic insufficiency * Diabetes (any type)

Locations (1)

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

Clinical improvement assessed by a validated questionnaire

Time frame: 2 weeks

Secondary Outcomes

Glucose, insulin, GLP1, GIP

Time frame: First and last evaluations

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.